247 related articles for article (PubMed ID: 8804418)
21. Urokinase-catalysed cleavage of the urokinase receptor requires an intact glycolipid anchor.
Høyer-Hansen G; Pessara U; Holm A; Pass J; Weidle U; Danø K; Behrendt N
Biochem J; 2001 Sep; 358(Pt 3):673-9. PubMed ID: 11535128
[TBL] [Abstract][Full Text] [Related]
22. Regulated localization confers multiple functions on the protease urokinase plasminogen activator.
Wells JM; Strickland S
J Cell Physiol; 1997 May; 171(2):217-25. PubMed ID: 9130470
[TBL] [Abstract][Full Text] [Related]
23. Binding of single-chain prourokinase to the urokinase receptor of human U937 cells.
Cubellis MV; Nolli ML; Cassani G; Blasi F
J Biol Chem; 1986 Dec; 261(34):15819-22. PubMed ID: 3023326
[TBL] [Abstract][Full Text] [Related]
24. Maspin retards cell detachment via a novel interaction with the urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor system.
Yin S; Lockett J; Meng Y; Biliran H; Blouse GE; Li X; Reddy N; Zhao Z; Lin X; Anagli J; Cher ML; Sheng S
Cancer Res; 2006 Apr; 66(8):4173-81. PubMed ID: 16618739
[TBL] [Abstract][Full Text] [Related]
25. Urokinase plasminogen activator and urokinase plasminogen activator receptor in breast cancer.
Duggan C; Maguire T; McDermott E; O'Higgins N; Fennelly JJ; Duffy MJ
Int J Cancer; 1995 May; 61(5):597-600. PubMed ID: 7768629
[TBL] [Abstract][Full Text] [Related]
26. Direct binding of occupied urokinase receptor (uPAR) to LDL receptor-related protein is required for endocytosis of uPAR and regulation of cell surface urokinase activity.
Czekay RP; Kuemmel TA; Orlando RA; Farquhar MG
Mol Biol Cell; 2001 May; 12(5):1467-79. PubMed ID: 11359936
[TBL] [Abstract][Full Text] [Related]
27. Receptor-mediated internalization and degradation of urokinase is caused by its specific inhibitor PAI-1.
Cubellis MV; Wun TC; Blasi F
EMBO J; 1990 Apr; 9(4):1079-85. PubMed ID: 2157592
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of the tumor-associated urokinase-type plasminogen activation system: effects of high-level synthesis of soluble urokinase receptor in ovarian and breast cancer cells in vitro and in vivo.
Magdolen V; Krüger A; Sato S; Nagel J; Sperl S; Reuning U; Rettenberger P; Magdolen U; Schmitt M
Recent Results Cancer Res; 2003; 162():43-63. PubMed ID: 12790320
[TBL] [Abstract][Full Text] [Related]
29. Plasminogen binding and activation at the breast cancer cell surface: the integral role of urokinase activity.
Stillfried GE; Saunders DN; Ranson M
Breast Cancer Res; 2007; 9(1):R14. PubMed ID: 17257442
[TBL] [Abstract][Full Text] [Related]
30. [The clinical prospects for the study of the plasminogen activation system in breast cancer].
Gershteĭn ES; Kushlinskiĭ NE
Vestn Ross Akad Med Nauk; 1999; (8):58-61. PubMed ID: 10487126
[TBL] [Abstract][Full Text] [Related]
31. Interaction of single-chain urokinase with its receptor induces the appearance and disappearance of binding epitopes within the resultant complex for other cell surface proteins.
Higazi AA; Upson RH; Cohen RL; Manuppello J; Bognacki J; Henkin J; McCrae KR; Kounnas MZ; Strickland DK; Preissner KT; Lawler J; Cines DB
Blood; 1996 Jul; 88(2):542-51. PubMed ID: 8695802
[TBL] [Abstract][Full Text] [Related]
32. The plasminogen activator/plasmin system is up-regulated after acute necrotizing pancreatitis in human beings.
Friess H; Duarte R; Kleeff J; Fukuda A; Tang WH; Graber H; Schilling M; Zimmermann A; Korc M; Büchler MW
Surgery; 1998 Jul; 124(1):79-86. PubMed ID: 9663255
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of receptor-bound urokinase by plasminogen-activator inhibitors.
Ellis V; Wun TC; Behrendt N; Rønne E; Danø K
J Biol Chem; 1990 Jun; 265(17):9904-8. PubMed ID: 2161846
[TBL] [Abstract][Full Text] [Related]
34. Structure, function and expression on blood and bone marrow cells of the urokinase-type plasminogen activator receptor, uPAR.
Plesner T; Behrendt N; Ploug M
Stem Cells; 1997; 15(6):398-408. PubMed ID: 9402652
[TBL] [Abstract][Full Text] [Related]
35. Reduction of breast carcinoma tumor growth and lung colonization by overexpression of the soluble urokinase-type plasminogen activator receptor (CD87).
Krüger A; Soeltl R; Lutz V; Wilhelm OG; Magdolen V; Rojo EE; Hantzopoulos PA; Graeff H; Gänsbacher B; Schmitt M
Cancer Gene Ther; 2000 Feb; 7(2):292-9. PubMed ID: 10770639
[TBL] [Abstract][Full Text] [Related]
36. Cathepsin B efficiently activates the soluble and the tumor cell receptor-bound form of the proenzyme urokinase-type plasminogen activator (Pro-uPA).
Kobayashi H; Schmitt M; Goretzki L; Chucholowski N; Calvete J; Kramer M; Günzler WA; Jänicke F; Graeff H
J Biol Chem; 1991 Mar; 266(8):5147-52. PubMed ID: 1900515
[TBL] [Abstract][Full Text] [Related]
37. Recombinant soluble urokinase receptor as a scavenger for urokinase-type plasminogen activator (uPA). Inhibition of proliferation and invasion of human ovarian cancer cells.
Wilhelm O; Weidle U; Höhl S; Rettenberger P; Schmitt M; Graeff H
FEBS Lett; 1994 Jan; 337(2):131-4. PubMed ID: 8287966
[TBL] [Abstract][Full Text] [Related]
38. The receptor for urokinase-type plasminogen activator of a human keratinocyte line (HaCaT).
Reinartz J; Link J; Todd RF; Kramer MD
Exp Cell Res; 1994 Oct; 214(2):486-98. PubMed ID: 7925643
[TBL] [Abstract][Full Text] [Related]
39. Subcellular distribution of urokinase and urokinase receptor in human neutrophils determined by immunoelectron microscopy.
Pedersen TL; Plesner T; Horn T; Høyer-Hansen G; Sørensen S; Hansen NE
Ultrastruct Pathol; 2000; 24(3):175-82. PubMed ID: 10914429
[TBL] [Abstract][Full Text] [Related]
40. A hybrid protein of urokinase growth-factor domain and plasminogen-activator inhibitor type 2 inhibits urokinase activity and binds to the urokinase receptor.
Ballance DJ; Marshall JM; Cottingham IR; Steven J; Berry SJ; Cederholm-Williams SA; Goodey AR; Courtney M
Eur J Biochem; 1992 Jul; 207(1):177-83. PubMed ID: 1321039
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
